IBRX Stock Price History and Quote Analysis Insights for Investors
ImmunityBio, Inc.
Stock Price Today
ImmunityBio, Inc. (IBRX) stock declined over -5.59%, trading at $2.87 on NASDAQ, down from the previous close of $3.04. The stock opened at $3.08, fluctuating between $2.82 and $3.12 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.
Company Information
| Employees | 672 |
| Beta | -0.43 |
| Sales or Revenue | $622.00K |
| 5Y Sales Change% | 1.059% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
ImmunityBio, Inc. (NASDAQ: IBRX) stock price is $2.87 in the last trading session. During the trading session, IBRX stock reached the peak price of $3.12 while $2.82 was the lowest point it dropped to. The percentage change in IBRX stock occurred in the recent session was -5.59% while the dollar amount for the price change in IBRX stock was -$0.17.
The NASDAQ listed IBRX is part of Biotechnology industry that operates in the broader Healthcare sector. ImmunityBio, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Barry J. Simon M.D.
Chief Corporation Affairs Officer & Director
Ms. Helen Luu
Chief Commercial Officer
Mr. Richard Gerald Adcock
Pres, Chief Executive Officer & Director
Dr. Leonard S. Sender M.D.
Chief Operating Officer
Dr. Hans Georg Klingemann M.D., Ph.D.
Chief Science Officer of Cellular
Dr. Patrick Soon-Shiong FACS, FRCS (C), M.Sc.
Executive Chairman, Global Chief Scientific & Medical Officer
Ms. Sarah Singleton
Chief Communications Officer
Dr. Enrique Diloné Ph.D., RAC
Chief Technology Officer
Mr. Jason R. Liljestrom
Gen. Counsel & Corporation Sec.
Mr. David C. Sachs
Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer
Dr. Patrick Soon-Shiong F.A.C.S., FACS, FRCS (C), M.Sc.
Executive Chairman, Global Chief Scientific & Medical Officer
Dr. Sandeep K. Reddy M.D.
Chief Medical Officer
IBRX's closing price is 1.95% higher than its 52-week low of $2.82 where as its distance from 52-week high of $10.53 is -72.75%.
Number of IBRX employees currently stands at 672.
Official Website of IBRX is: https://immunitybio.com
IBRX could be contacted at phone 858 633 0300 and can also be accessed through its website. IBRX operates from 3530 John Hopkins Court, San Diego, CA 92121, United States.
IBRX stock volume for the day was 8.8M shares. The average number of IBRX shares traded daily for last 3 months was 5.74M.
The market value of IBRX currently stands at $2.00B with its latest stock price at $2.87 and 696.83M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com